Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Safety and Efficacy Study of NUV-422 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT05191017 is registered in ClinicalTrials.gov with Nuvation Bio Inc. as lead sponsor.

NCT NCT05191017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05191017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Safety and Efficacy Study of NUV-422 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Lead sponsor
Nuvation Bio Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
September 30, 2022
Completion date
July 31, 2026
Enrollment
0 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of prostate, cancer of the prostate, castrate resistant prostate cancer, castration resistant prostatic cancer, castration resistant prostatic neoplasms, prostate cancer, prostate neoplasm, prostatic cancer